ClinicalTrials.gg
CompletedNCT01901393Updated Mar 14, 2016Results posted

Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery

A Phase 4 interventional study of IV ibuprofen and Ketorolac in Pain, sponsored by Cumberland Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-14.

Sponsored by Cumberland Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
42nd of 86
100 · median 100
Started
2013
with 3 others
Phase 4
30 of 86
3 open now
Registered
36th of 86
by date
Lead sponsor
6 of 86
Cumberland Pharmaceuticals

Among the 86 studies testing ibuprofen in Pain, this one is the 42nd largest by enrollment, is one of 4 that started in 2013, is one of 30 in phase 4, and was the 36th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of intravenous ibuprofen compared to ketorolac for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS)

03

Conditions studied

  • Pain

Keywords

  • Post Operative Pain,
  • Pail relief
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for knee arthroscopy

Exclusion criteria

Exclusion Criteria:

  • Inadequate IV access.
  • History of allergy or to any component of ibuprofen, ketorolac, aspirin (or aspirin related products), non-steroidal anti-inflammatory drugs (NSAIDs), opioids or cyclooxygenase-2 (COX-2) inhibitors.
  • Less than 18 years of age.
  • Use of analgesics less than 8 hours prior to surgery.
  • Patients with active, anemia.
  • History or evidence of asthma or heart failure.
  • Pregnant.
  • Recent history of chronic opioid use.
  • Concomitant use of probenecid.
  • Inability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions and to return for the required assessments.
  • Refusal to provide written authorization for use and disclosure of protected health information.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    IV ibuprofen

    800mg ibuprofen

    Drug: IV ibuprofen

  • Active comparator
    ketorolac

    30mg ketorolac

    Drug: Ketorolac

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Pain Relief (Pain Intensity at Rest)

    Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).

    Time frame: First possible time post-surgery, an expected average of 6 hours

  2. Efficacy of Pain Relief (Pain Intensity With Movement)

    Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).

    Time frame: First possible time post-surgery, an expected average of 6 hours

Secondary outcomes

  1. Rescue Medication Use in Post-operative Period

    Amount of rescue medication (in milligrams) will be measured

    Time frame: Post-operative period until discharge, an expected average of 6 hours

  2. Time to First Use of Rescue Med Will be Measured

    Time to first rescue medication (in hours) in the postoperative period through discharge.

    Time frame: Post-operative period until discharge, an expected average of 6 hours

  3. Patient Satisfaction

    Measured using 2 question, 4 point scale.

    Time frame: Post-operative period until discharge, an expected average of 6 hours

  4. Incidence of Serious Adverse Events

    Number of subjects experiencing treatment-emergent serious adverse events

    Time frame: Post-operative period until discharge, an expected average of 6 hours

07

Results

Posted Feb 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneIV IbuprofenKetorolac
Started5149
Completed5049
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryEfficacy of Pain Relief (Pain Intensity at Rest)

Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).

Time frame:
First possible time post-surgery, an expected average of 6 hours
Reported as:
Mean · units on a scale (in mm)
Efficacy of Pain Relief (Pain Intensity at Rest)
units on a scale (in mm)IV IbuprofenKetorolac
Efficacy of Pain Relief (Pain Intensity at Rest)30 ± 27.032 ± 25.1
SecondaryRescue Medication Use in Post-operative Period

Amount of rescue medication (in milligrams) will be measured

Time frame:
Post-operative period until discharge, an expected average of 6 hours
Reported as:
Mean · milligrams
Rescue Medication Use in Post-operative Period
milligramsIV IbuprofenKetorolac
Narcotic13.7 ± 17.1913.2 ± 16.50
Acetaminophen188.5 ± 255.06179.1 ± 248.77
SecondaryTime to First Use of Rescue Med Will be Measured

Time to first rescue medication (in hours) in the postoperative period through discharge.

Time frame:
Post-operative period until discharge, an expected average of 6 hours
Reported as:
Mean · hours
Time to First Use of Rescue Med Will be Measured
hoursIV IbuprofenKetorolac
Time to First Use of Rescue Med Will be Measured1.2 ± 0.111.2 ± 0.10
SecondaryPatient Satisfaction

Measured using 2 question, 4 point scale.

Time frame:
Post-operative period until discharge, an expected average of 6 hours
Reported as:
Number · Participants
Patient Satisfaction
ParticipantsIV IbuprofenKetorolac
Poor01
Fair48
Good2018
Excellent2622
SecondaryIncidence of Serious Adverse Events

Number of subjects experiencing treatment-emergent serious adverse events

Time frame:
Post-operative period until discharge, an expected average of 6 hours
Reported as:
Number · Number of events
Incidence of Serious Adverse Events
Number of eventsIV IbuprofenKetorolac
Incidence of Serious Adverse Events00
PrimaryEfficacy of Pain Relief (Pain Intensity With Movement)

Pain assessed using VAS (Visual Analog Scale, VAS). The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 (No Pain) and 100 (Worst Possible Pain).

Time frame:
First possible time post-surgery, an expected average of 6 hours
Reported as:
Mean · units on a scale (in mm)
Efficacy of Pain Relief (Pain Intensity With Movement)
units on a scale (in mm)IV IbuprofenKetorolac
Efficacy of Pain Relief (Pain Intensity With Movement)32 ± 28.041 ± 28.2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Ibuprofen—0/51 (0%)0/51 (0%)
Ketorolac—0/49 (0%)0/49 (0%)

Baseline characteristics

The Intent-to-Treat population consisted of all subjects who were enrolled and received at least a partial dose of investigational medicinal product.

Age, Continuous
Age, Continuous(years)IV IbuprofenKetorolacTotal
Mean45 ± 13.346 ± 15.546 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)IV IbuprofenKetorolacTotal
Female182139
Male332861
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV IbuprofenKetorolacTotal
Hispanic or Latino224
Not Hispanic or Latino494796
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV IbuprofenKetorolacTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American617
White444892
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IV IbuprofenKetorolacTotal
United States5149100
08

Study locations

4 sites
  • Shrock Orthopedic Research
    Fort Lauderdale, Florida 33316, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • North Mississippi Sports Medicine & Orthopaedic Clinic
    Tupelo, Mississippi 38801, United States
  • The Ohio State University Vexner Medical Center
    Columbus, Ohio 43210, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2013
First posted
Jul 17, 2013
Start
Jul 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Feb 15, 2016
Last update
Mar 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01901393
Responsible party
Sponsor
First posted
Jul 17, 2013
Start date
Jul 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Feb 15, 2016
Last update
Mar 14, 2016

Study contacts

Arthur P Wheeler, MD
study director · Cumberland Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion